Skip to content
Peptigraph home

Peptides for Cutting

The peptides people most often research for cutting, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Peptides listed
5
With human trials
4
FDA approved (any use)
3
Showing 5 peptides · ordered by search interest for this goal
  1. TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4Arthritis & rheumatology 2026, PMID 41903163Human89Animal4Summarised16FDA approved (Mounjaro, Zepbound)For cuttingOverview
  2. SemaglutideGLP-1 agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40934115Human151Animal20Summarised14FDA approved (Ozempic, Wegovy, Rybelsus)For cuttingOverview
  3. RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2026, PMID 42814954Human7Animal2Summarised13Investigational · phase 3For cuttingOverview
  4. TesamorelinGHRH analogHuman RCT evidence, 4 of 4eNeurologicalSci 2026, PMID 42382101Human15Animal0Summarised10FDA approved (Egrifta)For cuttingOverview
  5. IpamorelinGHRP (ghrelin receptor agonist)No study with an outcome for cuttingPubMed search, 11 Oct 2026Human0Animal1Summarised1Not FDA approved · research chemicalOverview
Read this first

What this list does not show

Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.

Search interest is not evidence

This list follows what people search for and discuss. It says nothing about how well any peptide works.

Animal results may not carry over

Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.

Approval covers specific uses

An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.

Combinations are a separate question

Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.

Cutting means losing fat while keeping muscle

MedlinePlus notes that body weight includes muscle, bone, fat and water.[8]

Fat loss is well documented for incretin drugs; muscle sparing is not

Tirzepatide has 89 human-only papers on cutting-related outcomes and semaglutide 151, while ipamorelin has none in people and tesamorelin has 15.

Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); tirzepatide human only 89, animal only 4, rct 11; semaglutide human only 151, animal only 20, rct 18; retatrutide human only 7, animal only 2, rct 1; tesamorelin human only 15, animal only 0, rct 6; ipamorelin human only 0, animal only 1, rct 0. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.

A tirzepatide trial of body composition found that fat mass fell by a much larger percentage than lean mass, though some lean mass was still lost.[9]

A pooled analysis described tirzepatide and semaglutide as among the least effective at preserving lean mass.[10]

In a retatrutide phase 2 trial, the proportion of lean mass loss to weight loss was similar to other obesity treatments.[11]

In people with HIV-related abdominal fat whose visceral fat fell on tesamorelin, skeletal muscle area and density increased.[12]

A review of physique peptides cites the absence of regulatory approval for physique- or performance-related indications and uncertainty over product composition, dose and stacking practices in unregulated supply chains.[13]

Common questions

What are the best peptides for cutting?

In a tirzepatide body-composition trial, fat mass fell 33.9% against 8.2% on placebo by week 72, and lean mass fell 10.9% against 2.6%.[9]

Do peptides help cutting without losing muscle?

Not shown: pooled data put tirzepatide and semaglutide among the least effective at preserving lean mass.[10]

Is there a peptide stack for cutting?

A physique-peptide review cites uncertainty over product composition, dose and stacking practices in unregulated supply chains.[13]

Sources

  1. 1Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  2. 2Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  3. 3Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026PMID 42814954Accessed 2 Oct 2026
  4. 4The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  5. 5PubMed search: ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  8. 8Official web pageOfficial web page · web page
  9. 9Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes, obesity & metabolism · 2025PMID 39996356Accessed 2 Oct 2026
  10. 10Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.Metabolism: clinical and experimental · 2025PMID 39719170Accessed 2 Oct 2026
  11. 11Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
  12. 12The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  13. 13The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026

Found an error? Report a correction.